Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

EWTX

Edgewise Therapeutics Inc

Last Close
38.90
Oct 30 • 3:59 PM ET Dollar change-0.01 Percentage change(-0.03%)
Aftermarket Close
39.10
Aftermarket • 5:15 PM ET Dollar change+0.20 Percentage change(0.51%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Mid NASD
Peers: CYTK DYN SRPT SLDB PTCT CAPR TNYA WVE BMY LXEO
 | Held by: VTI IWM VXF IWO IBB VTWO SCHA FESM DFAS IHE
Scroll to Statements
Index
RUT
Market Cap
4.22B
Enterprise Value
3.77B
Income
-197.22M
Sales
0.00M
Book/sh
4.16
Cash/sh
4.24
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
146
IPO
Mar 26, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
9.36
P/C
9.17
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
16.24
Current Ratio
16.24
Debt/Eq
0.01
LT Debt/Eq
0.01
Option/Short
Yes / Yes
EPS (ttm)
-1.85
EPS next Y
-1.64
EPS next Q
-0.53
EPS this Y
-26.01%
EPS next Y
20.17%
EPS next 5Y
-4.43%
EPS past 3/5Y
-8.91% -36.19%
Sales past 3/5Y
- -
EPS Y/Y TTM
-18.88%
Sales Y/Y TTM
-
EPS Q/Q
-54.68%
Sales Q/Q
-
Earnings
Aug 06 BMO
EPS/Sales Surpr.
-13.32% -
Insider Own
24.57%
Insider Trans
-1.11%
Inst Own
87.17%
Inst Trans
-0.16%
ROA
-36.09%
ROE
-38.03%
ROIC
-43.76%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-0.12%
SMA50
-5.90%
SMA200
7.24%
Trades
Shs Outstand
107.78M
Shs Float
81.92M
Short Float
14.35%
Short Ratio
8.12
Short Interest
11.75M
52W High
48.51 -19.81%
52W Low
16.33 138.21%
Volatility
4.61% 4.63%
ATR (14)
1.89
RSI (14)
45.70
Beta
0.39
Rel Volume
0.67
Avg Volume
1.45M
Volume
967,341
Perf Week
-1.04%
Perf Month
-3.90%
Perf Quarter
1.35%
Perf Half Y
27.08%
Perf YTD
56.76%
Perf Year
108.36%
Perf 3Y
469.55%
Perf 5Y
135.76%
Perf 10Y
-
Recom
1.29
Target Price
52.62
Prev Close
38.91
Price
38.90
Change %
-0.03%
Consensus
Strong Buy
Avg. Price Target
$52.62
Implied Upside
+35.3%
Analysts12incl. previous ratings
Rating Distribution9 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 16, 2026Initiated
WWilliam Blair
Outperform
Jul 09, 2026Initiated
OPY logoOOppenheimer
Outperform$51+31.1%
Sep 25, 2025Initiated
GS logoGGoldman
Neutral$20-48.6%
Jul 30, 2025Initiated
RJF logoRRaymond James
Strong Buy$46+18.3%
Jun 30, 2025Initiated
HH.C. Wainwright
Buy$42+8.0%
Apr 30, 2025Initiated
GGuggenheim
Buy$41+5.4%
Apr 02, 2025Downgrade
BNS logoBScotiabank
Sector Outperform → Sector Perform$14-64.0%
Mar 07, 2025Initiated
BNS logoBScotiabank
Sector Outperform$50+28.5%
Jan 22, 2025Initiated
SF logoSStifel
Hold$30-22.9%
Nov 22, 2024Initiated
EVR logoEEvercore ISI
Outperform$45+15.7%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donovan Joanne M.CMOAug 12 '26Option Exercise0.0012,812018,066Aug 14 04:54 PM
Donovan Joanne M.CMOAug 12 '26Sale43.856,522286,00011,544Aug 14 04:54 PM
Donovan Joanne M.CMOAug 13 '26Sale43.412,919126,7048,625Aug 14 04:54 PM
Russell Alan JChief Scientific OfficerAug 12 '26Option Exercise0.0012,812037,367Aug 14 04:53 PM
Russell Alan JChief Scientific OfficerAug 12 '26Sale43.735,901258,04231,466Aug 14 04:53 PM
MOORE JOHN RGeneral CounselAug 12 '26Option Exercise0.0012,499022,713Aug 14 04:53 PM
MOORE JOHN RGeneral CounselAug 12 '26Sale43.825,016219,82317,697Aug 14 04:53 PM
Derakhshan BehradChief Business OfficerAug 12 '26Option Exercise0.0013,281036,926Aug 14 04:53 PM
Derakhshan BehradChief Business OfficerAug 12 '26Sale43.815,100223,42431,826Aug 14 04:53 PM
KOCH KEVINPresident and CEOAug 12 '26Option Exercise0.0039,844070,459Aug 14 04:52 PM
KOCH KEVINPresident and CEOAug 12 '26Sale43.6817,971785,04252,488Aug 14 04:52 PM
JOANNE DONOVANOfficerAug 13 '26Proposed Sale43.562,919127,152Aug 13 04:31 PM
Russell Alan JChief Scientific OfficerJul 01 '26Option Exercise0.36200,00071,195224,555Jul 02 05:21 PM
Russell Alan JChief Scientific OfficerJul 01 '26Sale39.41200,0007,881,40224,555Jul 02 05:21 PM
ALAN J RUSSELLDirectorJul 01 '26Proposed Sale40.63200,0008,126,000Jul 01 04:55 PM
JOANNE DONOVANOfficerMay 05 '26Proposed Sale31.4550,0001,572,500May 05 04:29 PM
Donovan Joanne M.CMOMay 05 '26Option Exercise7.0850,000354,00054,367May 05 01:15 PM
Donovan Joanne M.CMOMay 05 '26Sale38.5750,0001,928,4004,367May 05 01:15 PM
Donovan Joanne M.CMOMay 04 '26Sale31.295,230163,6634,367May 05 01:15 PM
Donovan Joanne M.CMOApr 01 '26Option Exercise7.0828,662202,92738,259Apr 02 01:01 PM
Donovan Joanne M.CMOApr 01 '26Sale32.3128,662926,0959,597Apr 02 01:01 PM
Donovan Joanne M.CMOMar 31 '26Option Exercise7.0821,338151,07330,935Mar 31 07:33 PM
Donovan Joanne M.CMOMar 31 '26Sale32.1221,338685,3089,597Mar 31 07:33 PM
Donovan Joanne M.CMOMar 27 '26Sale30.9816,358506,7359,597Mar 30 05:32 PM
JOANNE DONOVANOfficerMar 27 '26Proposed Sale31.6571,5882,265,760Mar 27 04:41 PM
Edris BadreddinDirectorJan 21 '26Option Exercise1.47115,471170,264135,291Jan 23 01:34 PM
Edris BadreddinDirectorJan 21 '26Sale29.44115,4713,399,46619,820Jan 23 01:34 PM
Badreddin EdrisDirectorJan 21 '26Proposed Sale29.04115,4713,353,279Jan 21 04:05 PM
ROBERT MICHAEL CARRUTHERSOfficerJan 20 '26Proposed Sale28.11183,8675,168,722Jan 20 04:14 PM
ROBERT MICHAEL CARRUTHERSOfficerJan 15 '26Proposed Sale26.56180,8724,804,322Jan 15 04:45 PM
ROBERT MICHAEL CARRUTHERSOfficerDec 26 '25Proposed Sale26.06116,6653,039,812Dec 29 09:06 AM
ROBERT MICHAEL CARRUTHERSOfficerNov 17 '25Proposed Sale22.3870,0001,566,586Nov 17 04:38 PM
Russell Alan JChief Scientific OfficerNov 12 '25Option Exercise0.18100,00018,000123,400Nov 13 06:06 PM
Russell Alan JChief Scientific OfficerNov 12 '25Sale21.12100,0002,112,45023,400Nov 13 06:06 PM
Fox Jonathan CDirectorNov 11 '25Buy18.6410,700199,40323,702Nov 13 06:04 PM
ALAN J RUSSELLOfficerNov 12 '25Proposed Sale21.12100,0002,112,450Nov 12 04:58 PM
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.
M.D.Dr. Peter A. Thompson FACP
PresidentDr. Kevin Koch Ph.D.
Co-Founder & Independent DirectorDr. Badreddin Edris Ph.D.
Co-FounderDr. Alan J. Russell Ph.D.
Chief Financial OfficerMr. Michael P. Nofi
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)